Top 5 Clean Energy Startup Investors in France (May 2026)

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Investment focus

Industry: Biotechnology, Health Care, Pharmaceutical
Stage:Series B, Series A, Series C
Geography: United States, France, United Kingdom

Investor stats

Total investments: 190
Round size: Series A $7.3M–$50M; Series B $12M–$73M; Series C $12M–$60M
Lead/follow: 31% lead, 69% follow
Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
Alkeus Pharmaceuticals — Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Show all investments...

Amundi Private Equity Funds, an Amundi asset management subsidiary, specialises in private equity and unlisted infrastructure investments. Combining a wealth of expertise in all aspects of asset management built up over more than 10 years, Amundi provides both institutional and individual investors with a wide spectrum of investmentopportunities, ranging from direct fund investments in unlisted French and foreign companies to dedicated mandates and funds-of-funds for multi-management private equity and infrastructure investments. With more than 60 professionals based in Paris, Bucharest, Cairo, Casablanca, Tunis and Warsaw, Amundi Private Equity Funds assists companies at all stages of their development, the key objective being to offer fund subscribers yields in line with the best in the industry. At 31 December 2009, French and international subscribers had committed more than â‚¬3.7 billion to Amundi Private Equity Funds, making it a leading private equity player. The company owes its solid foundations to its positioning as part of a leading third-party asset management group of companies and to its membership of two international banking groups.

Investment focus

Industry: Software, E-Commerce, Biotechnology
Stage:Private Equity, Series A
Geography: France, India, Hungary

Investor stats

Total investments: 44
Round size: Series A $1.6M–$11M; Private Equity $2.7M–$123M
Lead/follow: 14% lead, 86% follow
Last fund: Likely still investing — raised $696M in 2021

Portfolio highlights

Vivalto Vie — Vivalto Vie is a privately held company that operates retirement homes in the Poitou-Charentes and Pays de la Loire regions.
Airtel — Bharti Airtel Limited, commonly known as Airtel, is an Indian multinational telecommunications services company headquartered in New Delhi, India. It operates in 20 countries across South Asia, Africa, and the Channel Islands. Airtel has a GSM network in all countries in which it operates, providing 2G, 3G and 4G services depending upon the countryof operation.Airtel is the largest provider of mobile telephony and second largest provider of fixed telephony in India, and is also a provider of broadband and subscription television services. It offers its telecom services under the "airtel" brand, and is headed by Sunil Bharti Mittal. Bharti Airtel is the first Indian telecom service provider to achieve Cisco Gold certification. It also acts as a carrier for national and international long distance communication services. The company has a submarine cable landing station at Chennai, which connects the submarine cable connecting Chennai and Singapore.
Les Opticiens Mobiles — Les Opticiens Mobiles is the first national network of opticians trained to intervene everywhere : at home, at work or in nursing homes or residences for elderly, both for working people and for fragile, isolated people.Covering the whole territory, the health professionals come to visit you with all the equipment needed. Based on an ethic chart,they offer services and products tailored to all : all types of glasses (eyeglasses, sunglasses, safety googles, contact lenses, hearing protection) with fixed prices, reimbursed by social welfare.

Show all investments...

Gimv is a European investment company with over three decades of experience in private equity and venture capital.Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 85 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employover 28,000 professionals.As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.More information on Gimv can be found on [www.gimv.com].

Investment focus

Industry: Biotechnology, Health Care, Medical
Stage:Series B, Private Equity
Geography: Belgium, United States, France

Investor stats

Total investments: 150
Round size: Series B $6M–$46M; Private Equity $7.5M–$80M
Lead/follow: 31% lead, 69% follow
Last fund: May invest from a new fund soon — raised $653M in 2010

Portfolio highlights

ERS — ERS is a semiconductor manufacturing company that offers thermal wafer testing and Air-Cool technology services.
Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is

Show all investments...

Siparex, France,s first multi-sectoral private equity investment company, is founded in Lyon.It was a start-up at a time when the spirit of enterprise was flagging. It emerged in one of France's regions, listed the shares of the original company one of its main vehicles on the stock market, grew internationally, and has become one of theindependent groups in its line of business in the space of 30 years.

Investment focus

Industry: Manufacturing, Software, Information Technology
Stage:Private Equity, Seed
Geography: France, United States, Italy

Investor stats

Total investments: 115
Round size: Seed $643k–$6.4M; Private Equity $5.4M–$31M
Lead/follow: 16% lead, 84% follow
Last fund: Likely still investing — raised $500M in 2021

Portfolio highlights

SILEANE — SILEANE is robotics, vision, and artificial intelligence. They offer to build machines to automate. They provide services that include robotique, vision industrielle, robotique adaptative, automatisation du geste, pick place, dévracage, traitement de surface, and intelligence artificielle.
E-Recycle — E-Recycle is an online and offline store that specializes in recycling used high-tech products such as mobile phones, tablets, and PCs.
Monet Associes — Monet + Associes is a public relations agency.

Show all investments...